{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:54:24Z","timestamp":1793120064184,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jhep.2024.06.027","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T21:38:20Z","timestamp":1720215500000},"page":"949-959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1914-5141","authenticated-orcid":false,"given":"Won Young","family":"Tak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-421X","authenticated-orcid":false,"given":"Wan-Lobg","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5438-2871","authenticated-orcid":false,"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chih","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-577X","authenticated-orcid":false,"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gin-Ho","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-7851","authenticated-orcid":false,"given":"Jeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui Lynn","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Vardeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Kopycinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Kolenovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9917-3363","authenticated-orcid":false,"given":"Thomas","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.06.027_bib1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.jhep.2024.06.027_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jfma.2018.11.008","article-title":"Taiwan consensus statement on the management of chronic hepatitis B","volume":"118","author":"Chien","year":"2019","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.jhep.2024.06.027_bib3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"2019 EASL-AASLD HBV treatment endpoints conference faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2024.06.027_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2024.06.027_bib5","doi-asserted-by":"crossref","first-page":"10377","DOI":"10.1128\/JVI.73.12.10377-10386.1999","article-title":"In\u00a0vivo regulation of hepatitis B virus replication by peroxisome proliferators","volume":"73","author":"Guidotti","year":"1999","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2024.06.027_bib6","doi-asserted-by":"crossref","first-page":"9652","DOI":"10.1128\/JVI.00867-09","article-title":"The size of the viral inoculum contributes to the outcome of hepatitis B virus infection","volume":"83","author":"Asabe","year":"2009","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2024.06.027_bib7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/vaccines8020184","article-title":"The design and development of a multi-hbv antigen encoded in chimpanzee adenoviral and modified vaccinia ANKARA viral vectors; a novel therapeutic vaccine strategy against HBV","volume":"8","author":"Chinnakannan","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.jhep.2024.06.027_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41541-020-00240-0","article-title":"Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans","volume":"5","author":"Capone","year":"2020","journal-title":"NPJ Vaccin"},{"key":"10.1016\/j.jhep.2024.06.027_bib9","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A\u00a0monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.06.027_bib10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiw244","article-title":"Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S\/AS01B with chimpanzee adenovirus 63 and modified vaccinia Ankara vectored vaccines expressing ME-TRAP","volume":"214","author":"Rampling","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2024.06.027_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhep.2024.06.027_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141687","article-title":"A\u00a0phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults","volume":"10","author":"Sheehan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.06.027_bib13","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of Chad63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2024.06.027_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","article-title":"Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)","volume":"11","author":"Mothe","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.jhep.2024.06.027_bib15","first-page":"382","article-title":"Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults","volume":"78","author":"Green","year":"2019","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.jhep.2024.06.027_bib16","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2024.06.027_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00011-010-0233-1","article-title":"Intrahepatic levels of PD-1\/PD-L correlate with liver inflammation in chronic hepatitis B","volume":"60","author":"Chen","year":"2011","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jhep.2024.06.027_bib18","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1053\/j.gastro.2012.08.041","article-title":"Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV","volume":"143","author":"Fisicaro","year":"2012","journal-title":"Gastroenterol."},{"key":"10.1016\/j.jhep.2024.06.027_bib19","article-title":"The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection","volume":"6","author":"Zhang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.06.027_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190058","article-title":"Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection","volume":"13","author":"Balsitis","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2024.06.027_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fimmu.2020.00401","article-title":"Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV Infection","volume":"11","author":"Hoogeveen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2024.06.027_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ctrv.2018.08.006","article-title":"Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy","volume":"74","author":"Chang","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhep.2024.06.027_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/EDBK_175230","article-title":"The promise of immunotherapy in the treatment of hepatocellular carcinoma","volume":"37","author":"El-Khoueiry","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jhep.2024.06.027_bib24","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.06.027_bib25","unstructured":"Cargill T, Cicconi P, Brown A, et\u00a0al. Therapeutic vaccine ChAdOx1-HBV is safe and immunogenic in healthy volunteers and patients with chronic Hepatitis B in phase 1 study HBV001. Hepatol. In press."},{"key":"10.1016\/j.jhep.2024.06.027_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00430-014-0376-8","article-title":"Therapeutic vaccines in HBV: lessons from HCV","volume":"204","author":"Barnes","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.jhep.2024.06.027_bib27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/mt.2014.15","article-title":"Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates","volume":"22","author":"Capone","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2024.06.027_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33375-1","article-title":"Development of a molecular adjuvant to enhance antigen-specific CD8+ T cell responses","volume":"8","author":"Halbroth","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2024.06.027_bib29","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1002\/jmv.26249","article-title":"Developing a sensitive HBV genotyping assay for HBV DNA suppressed patients using both DNA and RNA sequencing","volume":"92","author":"Liu","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2024.06.027_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cld.774","article-title":"Serum hepatitis B virus RNA as a potential diagnostic biomarker during chronic hepatitis B virus infection","volume":"13","author":"Cloherty","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.jhep.2024.06.027_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000099","article-title":"Measuring hepatitis B pgRNA stability using an updated automated HBV pgRNA assay with increased sensitivity","volume":"7","author":"Anderson","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2024.06.027_bib32","article-title":"Dynamics of hepatitis B virus pregenomic RNA in chronic hepatitis B Patients with antiviral therapy over 9 years","volume":"9","author":"Pan","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhep.2024.06.027_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01275-19","article-title":"Diagnostic value of detection of pregenomic RNA in sera of hepatitis B virus-infected patients with different clinical outcomes","volume":"58","author":"Lin","year":"2020","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2024.06.027_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01150-22","article-title":"Pregenomic RNA launch hepatitis B virus replication system facilitates the mechanistic study of antiviral agents and drug-resistant variants on covalently closed circular DNA synthesis","volume":"96","author":"Zhao","year":"2022","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2024.06.027_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2180-5-33","article-title":"Variability and conservation in hepatitis B virus core protein","volume":"5","author":"Chain","year":"2005","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jhep.2024.06.027_bib36","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0016-5085(99)70289-1","article-title":"Direct ex\u00a0vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection","volume":"117","author":"Maini","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.06.027_bib37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jiaa586","article-title":"Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized, controlled Phase 1 study","volume":"226","author":"Goldstein","year":"2022","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2024.06.027_bib38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.06.027_bib39","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1158\/1078-0432.CCR-16-2677","article-title":"Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40","volume":"23","author":"Messenheimer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2024.06.027_bib40","article-title":"PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy?","volume":"7","author":"Simon","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jhep.2024.06.027_bib41","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","article-title":"PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance","volume":"20","author":"Verma","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2024.06.027_bib42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.26376","article-title":"Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy","volume":"58","author":"Seto","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.06.027_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.gastro.2011.04.046","article-title":"Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters","volume":"141","author":"Tseng","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.06.027_bib44","first-page":"3308","article-title":"Usefulness of a hepatitis B surface antigen-based model for the prediction of functional cure in patients with chronic hepatitis B virus infection treated with nucleos(t)ide analogues: a real-world study","volume":"10","author":"Caviglia","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhep.2024.06.027_bib45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.06.027_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.06.027_bib47","first-page":"398","article-title":"A\u00a0predictive scoring system for the seroclearance of HbSAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection","volume":"66","author":"Liu J","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.06.027_bib48","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1136\/gutjnl-2021-324646","article-title":"Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection","volume":"71","author":"Aliabadi","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.06.027_bib49","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41598-020-58870-2","article-title":"Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2024.06.027_bib50","article-title":"Thyroid dysfunction is associated with the loss\u00a0of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with \u03b1-interferon","volume":"49","author":"Luo","year":"2021","journal-title":"J\u00a0Int Med Res"},{"issue":"6","key":"10.1016\/j.jhep.2024.06.027_bib51","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/jvh.13667","article-title":"Thyroid dysfunction incidence and risk factors in Chinese chronic hepatitis B patients treated with pegylated interferon alpha: a long-term follow-up study","volume":"29","author":"Ma","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2024.06.027_bib52","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2147\/IJGM.S261433","article-title":"Thyroid dysfunctions due to immune checkpoint inhibitors: a review","volume":"13","author":"El Sabbagh","year":"2020","journal-title":"Int J Gen Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782402333X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782402333X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:38:08Z","timestamp":1773967088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782402333X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S016882782402333X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.06.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}